Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study of Oral Almotriptan Malate (AXERT®) 6.25 mg, 12.5 mg, and 25 mg in the Acute Treatment of Migraine in Adolescents.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 May 2010
Price :
$35
*
At a glance
- Drugs Almotriptan (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Janssen Inc
- 05 Nov 2005 New trial record.